Faculty

Back to Index
David B. Agus, MD
Professor of Medicine
Director, Lawrence J. Ellison Institute For Transformative Medicine of Usc
Director, USC Center For Applied Molecular Medicine
Medicine
WMB 9033 Wilshire Blvd Health Sciences Campus Beverly Hills
+1 310 272 7640

Overview

Dr. David B. Agus is a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and the founding director of USC’s Lawrence J. Ellison Institute for Transformative Medicine.   Dr. Agus leads a multidisciplinary team of researchers dedicated to the development and use of technologies to guide doctors in making health-care decisions tailored to individual needs, and directs a National Cancer Institute Physical Sciences in Oncology Center at USC.  He is a medical oncologist and the co-founder of several personalized medicine companies. Dr. Agus is an international leader in new technologies and approaches for personalized healthcare, serving in leadership roles at the World Economic Forum, among other prestigious organizations. Dr. Agus’ first book called “The End of Illness” was published in 2012 and is a New York Times #1 and international best seller and was the subject of a PBS series, and his most recent books “A Short Guide to a Long Life” and “The Lucky Years: How to Thrive in the Brave New World of Health” are also New York Times and international bestsellers. Dr. Agus graduated cum laude with honors in molecular biology from Princeton University, and received his medical degree from the University of Pennsylvania School of Medicine. He completed his medical internship and residency training at Johns Hopkins Hospital.

Awards

Ellis Island Medal of Honor: Medalist, 2017

American College of Physicians: Fellow, 2016

USC Association of Trojan Leagues: Outstanding Service Award, 2013

Biotech Humanitarian Award: Selected Judge, 2009

Geoffrey Beene Foundation: Rock Stars of Scienceâ„¢, 2009

HealthNetwork Foundation: Excellence Award, 2008

American Cancer Society: Physician Research Award, 1996-2001

Sloan-Kettering Institute: Clinical Scholar Award, 1996

American Cancer Society: Clinical Oncology Fellowship Award, 1994

Publications

JUN-Mediated downregulation of EGFR signaling is associated with resistance to gefitinib in EGFR-mutant NSCLC cell lines. Mol Cancer Ther. 2017 May 31. View in: PubMed

Single cell dynamic phenotyping. Sci Rep. 2016 Oct 06; 6:34785. View in: PubMed

Quantifying differences in cell line population dynamics using CellPD. BMC Syst Biol. 2016 Sep 21; 10(1):92. View in: PubMed

A Plasma-Based Protein Marker Panel for Colorectal Cancer Detection Identified by Multiplex Targeted Mass Spectrometry. Clin Colorectal Cancer. 2016 Jun; 15(2):186-194. e13. View in: PubMed

THE DOCTOR WILL SEE YOU (AND YOUR DATA) NOW. Fortune. 2016 Jan 1; 173(1):90-3. View in: PubMed

The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older. PLoS One. 2016; 11(11):e0166103. View in: PubMed

A high-content image-based method for quantitatively studying context-dependent cell population dynamics. Sci Rep. 2016; 6:29752. View in: PubMed

Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS). Sci Rep. 2016; 6:22435. View in: PubMed

Aligning incentives to fulfil the promise of personalised medicine. Lancet. 2015 May 23; 385(9982):2118-9. View in: PubMed

Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Invest New Drugs. 2015 Apr; 33(2):397-408. View in: PubMed

Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. J Clin Oncol. 2015 Mar 1; 33(7):723-31. View in: PubMed

Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors. Psychooncology. 2015 Feb; 24(2):228-35. View in: PubMed

The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015; 14(Suppl 4):19-31. View in: PubMed

Phase I/II Trial of Orteronel (TAK-700)--an Investigational 17,20-Lyase Inhibitor--in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2014 Mar 1; 20(5):1335-44. View in: PubMed

Body image predicts quality of life in men with prostate cancer. Psychooncology. 2013 Apr; 22(4):756-61. View in: PubMed

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Apr; 31(2):409-16. View in: PubMed

Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013 Feb 15; 73(3):306-15. View in: PubMed

A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep. 2013; 3:1449. View in: PubMed

Perspective: Meeting of minds. Nature. 2012 Nov 22; 491(7425):S61. View in: PubMed

Reframe the health debate. Fortune. 2012 Oct 29; 166(7):22. View in: PubMed

A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol. 2012 Oct 10; 30(10):918-20. View in: PubMed

Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition. Mol Cancer Ther. 2012 May; 11(5):1071-81. View in: PubMed

Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs. 2012 Apr; 30(2):749-57. View in: PubMed

Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemother Pharmacol. 2012 Jan; 69(1):273-80. View in: PubMed

Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011 Dec 5; 8(6):2069-79. View in: PubMed

Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma. PLoS One. 2011; 6(7):e23090. View in: PubMed

Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 2011 Jan; 21(1):47-55. View in: PubMed

Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010 Sep; 56(9):1492-5. View in: PubMed

Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling. Prostate. 2010 Aug; 70(11):1201-10. View in: PubMed

Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. Mol Cancer Res. 2010 Jun; 8(6):809-20. View in: PubMed

HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res. 2010 Mar 1; 70(5):1989-99. View in: PubMed

Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 2009 Oct; 8(10):2882-93. View in: PubMed

Multiparameter computational modeling of tumor invasion. Cancer Res. 2009 May 15; 69(10):4493-501. View in: PubMed

Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping. Psychooncology. 2009 May; 18(5):508-14. View in: PubMed

ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics. 2008 Nov 1; 24(21):2534-6. View in: PubMed

Precursor-ion mass re-estimation improves peptide identification on hybrid instruments. J Proteome Res. 2008 Sep; 7(9):4031-9. View in: PubMed

Personalized genetics: a responsible approach. Am J Hum Genet. 2008 Jul; 83(1):130; author reply 131. View in: PubMed

The current state of preclinical prostate cancer animal models. Prostate. 2008 May 1; 68(6):629-39. View in: PubMed

Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res. 2007 Apr 1; 13(7):1979-86. View in: PubMed

Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007 Feb 20; 25(6):675-81. View in: PubMed

Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1208-15. View in: PubMed

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer. 2007; 7:142. View in: PubMed

Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery. Clin Adv Hematol Oncol. 2006 Jul; 4(7):541-9. View in: PubMed

Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int. 2006 Apr; 97(4):691-7. View in: PubMed

2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer. 2005 Dec 15; 104(12):2701-8. View in: PubMed

A perspective on protein profiling of blood. BJU Int. 2005 Sep; 96(4):477-82. View in: PubMed

Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc Natl Acad Sci U S A. 2005 Aug 16; 102(33):11858-63. View in: PubMed

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005 Apr 10; 23(11):2534-43. View in: PubMed

CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate. 2004 Nov 1; 61(3):228-35. View in: PubMed

PPARgamma signaling: one size fits all? Cell Cycle. PPARgamma signaling: one size fits all? Cell Cycle. 2004 Nov; 3(11):1352-4. View in: PubMed

Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell. 2004 Jun; 5(6):565-74. View in: PubMed

Ductal adenocarcinoma of the prostate. Clin Adv Hematol Oncol. 2004 Jun; 2(6):393-5; discussion 396. View in: PubMed

Targeting the HER-kinase axis in cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 3):9-20. View in: PubMed

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 1; 22(3):537-56. View in: PubMed

Update on HER-kinase-directed therapy in prostate cancer. Clin Adv Hematol Oncol. 2004 Jan; 2(1):53-6, 64. View in: PubMed

Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003 Jul 15; 63(14):4196-203. View in: PubMed

Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. J Natl Cancer Inst. 2002 Nov 6; 94(21):1641-7. View in: PubMed

Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res. 2002 Oct; 8(10):3226-31. View in: PubMed

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002 Aug; 2(2):127-37. View in: PubMed

TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene. 2002 Jul 18; 21(31):4739-46. View in: PubMed

Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood. 2002 May 15; 99(10):3748-55. View in: PubMed

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 2002 May; 8(5):986-93. View in: PubMed

CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. J Immunother (1991). 2001 May; 24(3):272-279. View in: PubMed

Powered bySC CTSI